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Native detection of protein O-GlcNAcylation by
gel electrophoresis†
Chuan Fu and Daan M. F. van Aalten *
O-GlcNAcylation is an abundant and dynamic protein posttransla-
tional modification (PTM), with crucial roles in metazoans. Studies
of this modification are hampered by the lack of convenient
methods for detecting native O-GlcNAcylation. Here, we describe
a novel gel-based approach, Separation of O-GlcNAcylated
Proteins by Polyacrylamide Gel Electrophoresis (SOPAGE), which
enables detection of O-GlcNAc levels and dynamics.
Introduction
Glycosylation of serine or threonine on nuclear and cyto-
plasmic proteins with O-linked β-N-acetyl-D-glucosamine
(O-GlcNAc) is an abundant, reversible and dynamic intracellu-
lar post-translational modification (PTM) that is essential for
metazoan life.1–4 The cellular O-GlcNAcylation cycle is regu-
lated by a pair of enzymes, O-GlcNAc transferase (OGT) and
O-GlcNAcase (OGA). Addition or removal of O-GlcNAc moieties
onto over 1000 proteins has been implicated in numerous cel-
lular processes, including transcription, cell cycle progression,
signal transduction, energy metabolism and protein quality
control.5–7 It also shows a degree of interplay with regulatory
protein phosphorylation, and serves as a link between nutrient
availability and cellular responses.8 O-GlcNAc is also essential
for embryogenesis and neuronal development,7,9 and abnor-
mal protein O-GlcNAcylation is implicated in diabetes,10
tumorigenesis,11 Alzheimer’s disease (AD)12 and X-linked intel-
lectual disability (XLID).13–15
Although O-GlcNAc was discovered more than 30 years ago,
there are only a few methods for monitoring its dynamics or
stoichiometry.16,17 Typically, O-GlcNAcylation does not give
rise to a detectable change of mobility on standard polyacryl-
amide gel electrophoresis (PAGE) due to the neutral charge of
O-GlcNAc residue and the minor addition of mass. Initially,
protein O-GlcNAc levels are quantified by radioactive label-
ing,18 high-pH anion exchange chromatography (HPAEC),19 or
lectin weak affinity chromatography (LWAC).20,21 However,
these methods are not routinely accessible, time-consuming or
requiring large quantities of samples. Western blotting using
O-GlcNAc specific antibodies (either pan-specific22 or site-
specific Abs23) can assess the relative change in protein
O-GlcNAc levels between samples, yet lacks the ability to
provide information on accurate quantification. Quantitative
mass spectrometry provides a solution; however, either
isotope-labeled peptides are required as internal standards for
MS1-based quantification,24 or precursor-fragment ions
couples and the fragmentation behavior of peptides derived
from proteins of interest must be pre-determined to facilitate
Multiple Reaction Monitoring Mass Spectrometry
(MRM-MS).25 Both these MS-based approaches require specific
reagents for each site to be monitored and are labor-intensive,
limiting their universal applicability. Recently, a mass-tag-
based derivatization method achieved the spatial separation of
O-GlcNAc protein in gels, facilitating quantification.26 The
O-GlcNAc is first labeled with a β-1,4-galactosyltransferase
mutant (Y289L) and azido-UDP-ketogalactose, and then
reacted with alkyne-containing polyethylene glycol (PEG) via
click chemistry. Here, accurate quantification relies on the
completeness of the requisite enzymatic and chemical reac-
tions, which can be affected by the diverse nature of the
protein substrates. Besides, wheat germ agglutinin (WGA)-
based affinity electrophoresis has recently been shown to
retard glycosylated protein in gels.27 However, WGA non-
specifically interacts with other types of glycosylation and has
low affinity for O-GlcNAc (approx. 10 mM for free O-GlcNAc28),
resulting in smeared bands. Functional dissection of O-GlcNAc
would benefit from a more universal method for the one-step
direct separation of O-GlcNAc subpopulations by gel electro-
phoresis but is still challenging.
Recently, we described an inactive mutant of the
O-GlcNAcase derived from Clostridium perfringens
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(CpOGAD298N), which was capable of binding O-GlcNAc pep-
tides and proteins specifically and with micromolar
affinities.29,30 CpOGAD298N can also act in a manner similar to
O-GlcNAc pan-specific antibodies, contributing to the develop-
ment of an O-GlcNAc enrichment and detection method at the
level of the whole proteome.6,31
Here, we describe the synthesis of acrylamide-pendant
inactive CpOGAD298N (AI-OGA) and its co-polymerization into
polyacrylamide gels. Using AI-OGA, we developed an
approach termed Separation of O-GlcNAcylated Proteins by
Polyacrylamide Gel Electrophoresis (SOPAGE). We demon-
strate that SOPAGE allows for the spatial separation of native
O-GlcNAc proteins from their unmodified counterparts, with
a mobility shift. This simple gel-based approach worked for
either single- or multi-site O-GlcNAc model proteins,
enabling the native detection of O-GlcNAcylation and deter-
mination of steady-state kinetics of OGT on native protein
substrates.
Results and discussion
Immobilized AI-OGA reduces O-GlcNAc protein electrophoretic
mobility
The principle of SOPAGE was outlined in Fig. 1a. The acryl-
group was chosen for functionalization of the inactive
CpOGAD298N mutant to prepare AI-OGA, because of its small
size, lack of charge, stability in the absence of initiators (e.g.,
TEMED), and compatibility with other components used in
PAGE. Synthesized AI-OGA was expected to copolymerize with
acrylamide and bis-acrylamide during gel casting, forming a
monolithic stationary phase. As such, O-GlcNAc proteins was
anticipated to show reduced electrophoretic mobility as a
result of continuous association-dissociation with immobi-
lized AI-OGA.
AI-OGA was synthesized in a two-step reaction (Fig. 1b).
Briefly, recombinant GST-CpOGAD298N expressed in E. coli
(Fig. S1†) was first reacted with sulfo-SMCC in HEPES buffer
(pH 7.5) to install maleimide groups onto the ε-amino group
of lysine residues. Thereafter, excessive sulfo-SMCC was
removed with NAP-5 column, and the buffer was changed to
MES buffer (pH 5.2) to facilitate the subsequent reaction.
Meanwhile, the disulfide bond in N,N′-bis(acryloyl)cystamine
was reduced with TCEP in a parallel tube, and the resulting
product with free thiol was added to maleimide-GST-
CpOGAD298N to yield AI-OGA.
The resulting AI-OGA was characterized by function-based
assays and mass spectrometry. First, we casted a two-layer gel
with AI-OGA added to the upper-layer during polymerization
(Fig. S2†). After electrophoresis, the gel was stained with
Coomassie Blue to visualize the protein. As shown in Fig. 2a,
the addition of AI-OGA did not affect gel polymerization,
giving a monolithic gel sheet. Electrophoresis did not blur the
boundary between the two layers (Fig. 2a), suggesting the
absence of any non-functionalized GST-CpOGAD298N and unpo-
lymerized AI-OGA. Subsequently, we demonstrated that
AI-OGA undergoing the above chemical modification still
retained its affinity for O-GlcNAc proteins by using gel-shift
assays, in which AI-OGA formed a stable protein complex with
a model protein gTAB1, but not with TAB1 (Fig. 2b and S3†).
The acrylamide-modified sites of AI-OGA were then mapped
with mass spectrometry and shown in Fig. 2c and detailed in
ESI (Fig. S4 and Excel file).†
To assess the feasibility of SOPAGE analysis, AI-OGA was
added at a concentration of 2 µM to the conventional gel
mixture prior to initiation of polymerization with TEMED. As
Fig. 1 Schematic of the SOPAGE method (a) and synthesis of AI-OGA (b).
Fig. 2 Characterization of AI-OGA. (a) Two-layer gels with AI-OGA
added to the upper-layer at indicated concentration. The clear interface
between two layers was indicated with arrow. (b) AI-OGA/gTAB1
complex revealed by gel-shift assay. Briefly, 10 pmol AI-OGA was mixed
with 15 pmol of TAB1 or gTAB1. The mixture was subjected to native-
PAGE and the stable complex was indicated with asterisk. (c) Acrylamide
modified lysine residues on AI-OGA. The AI-OGA structure was mod-
elled with PHYRE2 software using PDB 2CBJ and 4AKG as templates.
11 modified lysine with a Delta score > 40 were labelled in red. 6 of
these sites located in the GST region.
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such, AI-OGA was covalently and uniformly embedded in a gel.
Three model protein samples (TAB1, gTAB1 and gTAB1 treated
with wild type CpOGA) were used for validation. TAB1, which
acts as a signalling intermediate between TGFβ receptors and
TAK1, is O-GlcNAcylated on Ser395, providing an ideal model
for studying proteins with single O-GlcNAc moieties.23 gTAB1
was prepared by an in vitro reaction with OGT, followed by size-
exclusion chromatography to remove OGT. Complete conver-
sion of TAB1 to gTAB1 was achieved by adding an excess of
OGT over prolonged reaction times (∼3 days). After that, pro-
teins were subjected to SOPAGE, and then electroblotted onto
nitrocellulose membranes. The addition of 0.04% (w/v) SDS to
the transfer buffer was necessary for disrupting the interaction
between the immobilized AI-OGA and O-GlcNAc proteins, facil-
itating electrotransfer. The membrane was then visualized
with a mixture of anti-TAB1 and anti-gTAB1 antibodies. As
shown in Fig. 3a, gTAB1 exhibited slower migration than TAB1,
resulting in a markedly up-shifted band. Treatment of gTAB1
with CpOGA eliminated this migratory retardation. In
addition, the level of separation of TAB1 and gTAB1 bands cor-
related with the AI-OGA concentration used in the gel (Fig. 3b).
We next evaluated SOPAGE for multi-O-GlcNAcylated protein.
To this end, the first PRO repeat of host cell factor 1 (HCF1-
rep1) which bears >20 O-GlcNAc sites was chosen as a
model.32 As a result, HCF1-rep1 was also spatial separated
from its O-GlcNAcylated counterpart (Fig. S5†). Taken together,
these data show that immobilized AI-OGA reduces the electro-
phoretic mobility of O-GlcNAc proteins, paving the way for
native detection of O-GlcNAc levels.
SOPAGE quantification of O-GlcNAc stoichiometry allows
determination of OGT kinetics
We next attempted to use SOPAGE to measure the kinetics of
OGT on intact protein substrates. To this end, we first used
SOPAGE to monitor the in vitro conversion of TAB1 over time
by OGT. As shown in Fig. 4, approximate 70% of TAB1 was con-
verted to gTAB1 within 24 h, which was consistent with recent
results obtained by native protein MS.33
Next, a series of OGT reactions were set up with varying con-
centrations of TAB1, while the concentrations of hOGT and
UDP-GlcNAc were kept constant. After SOPAGE and western
blotting, the spatially separated TAB1 and gTAB1 bands in
each lane were developed using anti-TAB1 as the sole primary
antibody to allow signals to be compared. The band intensities
of TAB1 (Ifast) and gTAB1 (Islow) were quantified, and the frac-
tion of gTAB1 (gTAB1%) in each individual reaction was calcu-
lated by the following formula:
gTAB1 % ¼ Islow
Islow þ Ifast
Plotting of initial velocities against TAB1 concentration
allowed us to establish steady-state kinetics (Fig. 4c). Unlike
when short peptides were used as substrates, this curve did
not reach a plateau. Accordingly, we used a previously reported
double-reciprocal plotting to calculate the kinetic para-
meters.18 The maximum velocity (Vmax), the apparent
Michaelis constant (Km,app) and the catalytic rate constant
(kcat) of hOGT for TAB1 were 37.52 nmol mg
−1 min−1, >1 mM
and 0.052 s−1, respectively. Taken together, SOPAGE quantifi-
cation of O-GlcNAc stoichiometry allows determination of OGT
kinetics using intact TAB1 as a substrate.
SOPAGE applies to a wide dynamic range of O-GlcNAc levels
In the above kinetics experiment, only low levels of O-GlcNAc
modification (<10% turnover) were used to maintain steady-
state conditions. We next challenged SOPAGE with samples of
near-stoichiometric O-GlcNAc modification. In such cases, if
the affinity of the ligand (AI-OGA in this study) was too weak,
or the ligand co-migrated with O-GlcNAc proteins due to un-
immobilization, the theoretical plate number of SOPAGE gel
will decline,34 resulting in the failure to retard O-GlcNAc
species. Besides, the applicability of SOPAGE to other types of
proteins also needed to be evaluated. To this end, we chose
substrate-hOGT fusions as models in which peptides derived
from the widely studied O-GlcNAc proteins (TAB1, CK2, and
CRMP2) were fused to the OGT N-terminus, yielding TAB1-
hOGT, CK2-hOGT and CRMP2-hOGT, respectively. As we pre-
viously reported, these fusions were auto-glycosylated using
Fig. 4 Measuring OGT kinetics by SOPAGE. (a) Monitoring hOGT reac-
tion dynamics by SOPAGE. The signal was visualized with a mixture of
TAB1 and gTAB1 Abs. (b) The conversion of TAB1 to gTAB1 by hOGT over
time. (c) Determination of OGT steady-state kinetics for TAB1. The reac-
tions were carried out with 0.17–41 μM TAB1, 100 μM of UDP-GlcNAc
and 0.45 μM of hOGT at 37 °C for 1 h. After SOPAGE and blotting with
TAB1 Abs, TAB1 and gTAB1 were quantified with Image Studio software.
Kinetic parameters were calculated by double-reciprocal plotting. The
turnover was <10% in all reactions. Assays in a-c were in triplicate.
Fig. 3 (a) Spatial separation of gTAB1 and TAB1 by SOPAGE. TAB1 was
O-GlcNAcylated by hOGT to yield gTAB1. OGA treatment of gTAB1
rescued such retardation. (b) The migration distance between TAB1 and
gTAB1 bands separated by SOPAGE was associated with the AI-OGA
concentration (0–4 μM).
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endogenous UDP-GlcNAc as the donor during expression in
E. coli, and showed high O-GlcNAc stoichiometry.35 We used
these proteins together with an HCF1-hOGT fusion lacking an
glycosylation site as a negative control, together with CpOGA
treatment, in a SOPAGE experiment.
As a result, the migration patterns of TAB1-hOGT, CK2-
hOGT and CRMP2-hOGT were changed after CpOGA treat-
ment, but not that of the negative control HCF1-hOGT (Fig. 5).
Besides, the band intensities corresponding to the non-glyco-
sylated forms were increased. The overall O-GlcNAc levels of
these proteins purified from E. coli was determined to be 90 ±
5%, 58 ± 4%, and 58 ± 5%, based on triplicates. Taken
together, these data show determination of O-GlcNAc levels by
SOPAGE covers a wide dynamic range.
Conclusion
Compared to the limited methods developed for determining
native protein O-GlcNAc stoichiometry, SOPAGE offers a
number of advantages. First, SOPAGE only requires the
addition of the AI-OGA monomer, obtainable to large quan-
tities by recombinant expression (>40 mg L−1), to a standard
PAGE gel. Second, SOPAGE does not require sophisticated
sample processing by chemical and/or enzymatic methods, or
any advanced equipment (e.g., mass spectrometer or radio-
active detector) beyond a standard protein electrophoresis set
up. This makes SOPAGE more convenient and economical that
is accessible to any laboratory. Third, the inherent high affinity
of CpOGAD298N, and its higher specificity than other affinity-
ligands, such as WGA or succinylated WGA (sWGA), makes
this approach specifically suitable for O-GlcNAc analysis.30 In
most cases, a thin layer of SOPAGE gel (∼5 mm in length)
between the stacking and separation gel was sufficient to sep-
arate O-GlcNAc proteins into a sharp band. In general, the
detection limitation of SOPAGE is similar to that of conven-
tional western blotting and is limited by the antibodies and
instruments used (e.g. Li-Cor, chemiluminescence scanner or
film) Last but not least, SOPAGE was compatible with many
existing technologies because of the electrophoretic basis. For
instance, in the future, SOPAGE could be combined with the
Phospho-tag gel36 to differentiate phosphorylated and
O-GlcNAcylated protein on the same gel, or integrated into
“on-chip” electrophoresis and “μWestern” technology37 to
enable miniaturization and automation of analysis.
In summary, a facile, versatile, and economical gel-based
method was developed for measuring OGT kinetics on protein
substrates and determining native protein O-GlcNAc levels.
This high-performance approach involved the retardation of
electrophoretic mobility of O-GlcNAc proteins by immobilized
O-GlcNAcase inactive mutant AI-OGA copolymerized with acryl-
amide/bis-acrylamide. In the future, the synthesized AI-OGA
monomer could be exploited to develop a next-generation
matrix for weak affinity chromatography. We envision that
SOPAGE will be a useful tool to help to advance the under-
standing of the physiological functions of O-GlcNAcylation.
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